1. Relative Bioavailability Risk Assessment: a Systematic Approach to Assessing In Vivo Risk Associated With CM&C-Related Changes;Aburub;J. Pharm. Sci.,2019
2. The effect of mannitol on the oral bioavailability of cimetidine;Adkin;J. Pharm. Sci.,1995
3. Guidance for industry: Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations;Administration, F.a.D.,,1997
4. Administration, U.F.a.D., 1997b. Guidance for Industry. SUPAC-MR: Modified Release Solid Oral Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation. US Department of Health and Human Services, Center for Drug Evaluation and Research (CDER).
5. Guidance for Industry: Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs — General Considerations;Administration, U.F.a.D.,,2014